The development of small-molecule inhibitors of the epidermal growth factor receptor (EGFR), such as erlotinib and gefitinib, for the treatment of advanced non–small-cell lung cancer illustrates a pattern of initial overly enthusiastic interest, subsequent critical disappointment, and eventual renewed appreciation of the clinical and mechanistic complexities surrounding the introduction of a new therapy for cancer. Such a pattern has been regrettably common in the history of oncologic therapeutics.
吉非替尼，埃洛替尼等小分子抑制剂在治疗晚期的非小细胞肺癌（表皮生长因子受体）的过程中，经历了，初期过于热情利息、后续的非常失望和最终再次的肯定这个复杂的过程。这是作为介绍新的临床的和机理复杂的治疗癌症的方法的方式。这种方式不得不说是常见于肿瘤学疗法的历史中的。
The initial safety and efficacy studies of erlotinib and gefitinib evoked a remarkable degree of optimism that was based on prolonged remissions and, in some cases, dramatic improvements in the quality of patient’s life.
埃洛替尼与吉非替尼的初步疗效和安全性激起了很大的研究热情，这主要是基于这两种药物可以显著延长患者生命和改善病人的生活质量。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
